NY-AMERICAN-EXPRESS
21.3.2022 14:02:44 CET | Business Wire | Press release
American Express (NYSE:AXP) released the American Express Travel: 2022 Global Travel Trends Report 1 today, which shows people are looking forward to more trips than last year and planning to spend more or the same on travel in 2022 compared to a typical pre-pandemic year. The report, based on data from the United States, Australia, Canada, Mexico, Japan, India and the United Kingdom, reveals consumers are traveling to see the people and places they love, celebrate important life events, embark on wish list trips, experience in-person events, and to seek greater wellness and self-care. In Q4 2021, global Card Member bookings made through American Express Travel were up 24% compared to 2019 and have continued to strengthen in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005163/en/
“The pandemic has made all of us, including travelers, assess what is truly important,” said Audrey Hendley, President of American Express Travel. “The Global Travel Trends Report shows that tourists are making up for lost time and being thoughtful about who they travel with, the places they visit, the brands they support, and how they spend their money as the travel industry moves forward.”
Top insights from the American Express Travel: 2022 Global Travel Trends Report1 include:
- The world is ready to travel: 74% of respondents agree they are willing to book a trip for 2022 even if they might have to cancel or modify it later1 . This is up from 56% last year2 .
- Spending on travel is outpacing pre-pandemic levels : 86% of consumers expect to spend more or the same on travel in 2022 compared to a typical pre-pandemic year1 .
- Tourists want to travel more frequently: 62% of respondents plan on taking 2-4 trips in 2022 and 76% of respondents agree they plan to travel more with family in 2022 than they did in 2021.
- Tourists are seeking out brands that prioritize supporting local communities: 81% of respondents want to visit destinations where they can immerse themselves in the local culture and want the money they spend while traveling to go back to the local community.
- Dream destinations are becoming a reality: 55% of respondents want to book a once-in-a-lifetime vacation this year; especially true for Millennials (67%) and Gen Z (65%).
- As entertainment returns so do trips tied to in-person events: 56% of respondents stated they held off on traveling for major entertainment events last year but have plans to return to these types of events this year.
As travel momentum continues to grow, American Express Travel offers exclusive access and value, unique programs and benefits, and access to best-in-class travel expertise through American Express Travel Consultants who back Card Members with any type of trip.
The full American Express Travel: 2022 Global Travel Trends Report can be found here .
1 Survey Methodology: This Amex Trendex online poll was conducted by Morning Consult between February 3- 11th, 2022 among a national sample of 2,000 US and 1,000 travelers in Australia, Canada, India, Japan, Mexico, the UK, and the US who have a household income of at least $70K and defined as adults who typically travel by air at least once a year. Results from each market’s survey have a margin of error of plus or minus 3 percentage points.
2 Survey Methodology: This Amex Trendex online poll was conducted by Morning Consult between January 15-24, 2021 among a national sample of 1,000 travelers in Australia, Canada, India, Japan, Mexico and the U.K., and 2,000 in the U.S. $70k+ USD household income (HHI) equivalent in Australia, Canada, Japan, the U.K. and the U.S., $50k+ USD equivalent HHI in Mexico, and $20k+ USD equivalent household income in India. Travelers defined as adults who traveled by air at least once in 2019. Results have a margin of error of plus or minus 2 percentage points in the U.S.; plus or minus 3 percentage points in the other countries.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress , instagram.com/americanexpress , linkedin.com/company/american-express , twitter.com/americanexpress , and youtube.com/americanexpress .
Key links to products, services and corporate responsibility information: personal cards , business cards , travel services , gift cards , prepaid cards , merchant services , Accertify , Kabbage , Resy , corporate card , business travel , diversity and inclusion , corporate responsibility and Environmental, Social, and Governance reports .
Location: Global
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005163/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom